For loading of OVA into AEP-MSNs, OVA (0.5 mL, 0.5 mg/mL‚ 1 mM PB) and AEP-MSN (0.5 mL, 2 mg/mL, 1 mM PB) were mixed and incubated in
Eppendorf mixer (400 rpm, 25°C, Nijmegen, the Netherlands) for different time periods (0, 0.5, 1, 2, 4, 8 and 24 h). After incubation, the suspensions were centrifuged and the encapsulation efficiency (EE%) of OVA was determined by measuring the difference in its intrinsic fluorescence intensity with a plate reader (Tecan
M1000, Männedorf, Switzerland) (excitation wavelength = 280 nm and emission wavelength = 320 nm) in the supernatant before and after the encapsulation.
To determine the maximum loading capacity (LC%) of OVA in AEP-MSNs, the AEP-MSNs (2 mg/mL) were mixed with different initial concentrations of OVA (ranging from 0.25, 0.5, 1, 1.5, 2 to 3 mg/mL) and incubated in an
Eppendorf mixer (400 rpm, 25°C) for 0.5 h. Next, the suspensions were centrifuged at 9000 g for 5 min. The EE% of OVA was determined by measuring the difference in their intrinsic fluorescence intensity in the supernatant before and after the encapsulation with a plate reader (Tecan
M1000).
The EE% and LC% were calculated as below:
Where
tova represents the total content of OVA, and
fova is the content of free OVA (OVA in the supernatant).
Tu J., Du G., Reza Nejadnik M., Mönkäre J., van der Maaden K., Bomans P.H., Sommerdijk N.A., Slütter B., Jiskoot W., Bouwstra J.A, & Kros A. (2017). Mesoporous Silica Nanoparticle-Coated Microneedle Arrays for Intradermal Antigen Delivery. Pharmaceutical Research, 34(8), 1693-1706.